Whilst most of those working in the pharmaceutical industry have felt the pressures of rising costs and thinning pipelines over the last twenty years, some entrepreneurial souls have managed to turn a ...

In an ambitious move, Moderna has teamed up with OpenAI, the artificial intelligence company behind ChatGPT, to further integrate generative AI (GenAI) across its mRNA drug development and ...

Alkermes' alixorexton has become the first drug in the orexin 2 receptor agonist class to show efficacy in phase 2 trials involving patients with both main subtypes of sleep disorder narcolepsy.

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product. The FDA has given ...

The FDA has instructed Pfizer and Moderna to add stronger warnings to the labels of their COVID-19 vaccines about the risk of cardiotoxicity in some patients, citing a recent study and new data. While ...

AstraZeneca is mourning the loss of one of its top scientists after eminent cancer researcher José Baselga passed away at the age of just 61. Baselga was a heavyweight in oncology research, pursuing a ...

Novartis' programme providing free access to its spinal muscular atrophy (SMA) gene therapy Zolgensma is being scaled back to a dozen countries worldwide, according to the company. First introduced in ...

A more interesting explanation is that pharma’s presence at the Super Bowl is about more than poor timing or mass market blockbusters. It might represent a sea change in how pharma is presenting ...

Sam Possemiers, CEO of MRM Health, believes that the space is finally coming into maturity. At his own company, that’s in the ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...

Bayer is vying to be first to market in the oral Factor XIa category against Bristol Myers Squibb and Johnson & Johnson, ...